Aumolertinib plus bevacizumab for untreated advanced NSCLC with EGFR sensitive mutation
BackgroundAumolertinib is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) with proven efficacy and safety for untreated non-small-cell lung cancer (NSCLC) patients with EGFR sensitizing mutations (EGFRm) in China. The progression-free survival (PFS) imp...
Tallennettuna:
| Päätekijät: | , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2025-06-01
|
| Sarja: | Frontiers in Oncology |
| Aiheet: | |
| Linkit: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1595812/full |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|